Compare Microsoft (MSFT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Novartis AG — how do they compare? Microsoft trades at $501.64 (market cap $3.76T), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Microsoft is far larger — about 12.6× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| MSFT | NVS | |
|---|---|---|
Market Cap | $3.76T | $298.18B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $168.62 |
52-Week Low | $352.83 | $118.55 |
Enterprise Value | $3.74T | $339.50B |
Dividend Yield | 0.72% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $506.06, up 1.21% today, near its pivot point of $507. The stock shows strong bullish momentum with consistent earnings beats, including Q2 2026 EPS of $4.74 versus $4.24 expected. Revenue growth accelerated to $281.72B in 2025, with a net income margin of 40.31%. Analysts maintain an 80.49% buy rating, citing AI leadership via Azure and Copilot.
Outlook remains positive with a consensus price target of $553.70, though risks include high capital expenditures and competitive pressures in AI. The stock's valuation multiples like P/E of 28.19 are elevated, requiring sustained execution. Near-term support lies at $500, with resistance at $513.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
